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Abstract
Background: Preventing HIV transmission is a worldwide public health issue. Vertical
transmission of HIV from a mother can be prevented with diagnosis and treatment, but screening
incurs cost. The U.S. Virgin Islands follows the mainland policy on antenatal screening for HIV even
though HIV prevalence is higher and rates of antenatal care are lower. This leads to many cases of
vertically transmitted HIV. A better policy is required for the U.S. Virgin Islands.
Methods: The objective of this research was to estimate the cost-effectiveness of relevant HIV
screening strategies for the antenatal population in the U.S. Virgin Islands. An economic model was
used to evaluate the incremental costs and incremental health benefits of nine different
combinations of perinatal HIV screening strategies as compared to existing practice from a societal
perspective. Three opportunities for screening were considered in isolation and in combination: by
14 weeks gestation, at the onset of labor, or of the infant after birth. The main outcome measure
was the cost per life year gained (LYG).
Results: Results indicate that all strategies would produce benefits and save costs. Universal
screening by 14 weeks gestation and screening the infant after birth is the recommended strategy,
with cost savings of $1,122,787 and health benefits of 310 LYG. Limitations include the limited
research on the variations in screening acceptance of screening based on specimen sample, race
and economic status. The benefits of screening after 14 weeks gestation but before the onset of
labor were also not addressed.
Conclusion: This study highlights the benefits of offering screening at different opportunities and
repeat screening and raises the question of generalizing these results to other countries with
similar characteristics.
Background
Perinatal transmission causes most HIV infection among
new born infants [1]. Transmission occurs during preg-
nancy, at the time of delivery or through breast milk [2].
The risk of perinatal HIV transmission can be reduced
from 13–43% to less than 2% [3-5] if an accurate diagno-
sis is made and appropriate treatment provided. Universal
antenatal screening for HIV in pregnancy is now advo-
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effectiveness studies have been published [8-12]. These
describe high income settings where HIV prevalence is
low, prenatal care is widely available and adherence is
good and typically screening is offered once during the 1st
trimester [8,9,13]. There is also literature that describes
low income countries where the HIV prevalence is high
but health resources are quite scarce making treatment
options limited after diagnosis [10,11]. There is little
research for settings where prevalence is relatively high
and adherence to prenatal care is low, yet resources are
available to make an accurate diagnosis and deliver effec-
tive therapy. In this case there is a clinical rationale for
offering a diagnostic test to women who present in the
first trimester and again at the onset of labour and for the
rapid testing of infants. The process of repeat screening
will overcome the problem of poor adherence to prenatal
care and also captures women who may not have serocon-
verted at the time of the first test and women who contract
the virus after the first screen. There is evidence that risks
of perinatal transmission can be mitigated if a diagnosis is
made at the onset of labor [14,15] and if the infant is
screened [2,16], however, repeat screening regimens will
incur costs and these must be balanced against health
benefits.
In the U.S. Virgin Islands, less than 70% of women
received antenatal care within the first trimester and of
these women, less than 30% are screened for HIV [17,18].
The aim for this study is to develop a model of the incre-
mental costs and incremental health benefits of nine dif-
ferent combinations of perinatal HIV screening strategies
compared to existing practice. Three screening opportuni-
ties and all logical combinations are evaluated. These
include screening by 14 weeks gestation during prenatal
care, screening at the onset of labour and screening of the
infant within 24 hours of birth. An alternative to the
Enzyme Linked Immunoassay (EIA) screening tests is also
considered, this is a rapid point of care test (Orasure®).
The setting is the U.S. Virgin Islands which is an upper
income setting, although on the low end of the World
Bank classification scale (GDP US$15,000 per capita
[19]). It has a population of around 110,000, over 1500
births per year [20], and has relatively high prevalence of
antenatal HIV. It is a U.S. territory with many of its health
policies adopted from the mainland U.S. even though its
population characteristics and resource availability is con-
siderably different. The results from this study can be gen-
eralized to other settings where prevalence is relatively
high, adherence to prenatal care is poor yet resources are
available for screening and treatment.
Methods
Overview
A cost-effectiveness decision-analytic model was built
using TreeAge Pro®. A societal perspective was adopted to
include the relevant health service costs, private costs and
production losses. The expected incremental costs and
health benefits, expressed as life years gained, of all logical
alternate screening strategies were compared to existing
practice at the decision node. See Figure 1 for a list of the
strategies evaluated. The following uncertain events were
built into the tree: HIV negative versus HIV positive
woman; woman seeks prenatal care versus doesn't seek
prenatal care; woman accepts screening versus declines
screening; HIV test positive versus negative; pregnancy ter-
minated versus not terminated; woman accepts ART ther-
apy versus declines ART; HIV averted in infant versus HIV
positive infant. All cost and benefit data was collected for
a reference year of 2004 and were counted in $US. Data
values were verified by local experts where relevant. All
future costs and benefits were discounted at a rate of 3%
in line with current recommendations [21]. Ethical per-
mission for the study was granted by the Queensland Uni-
versity of Technology Research Ethics Committee.
Incremental Costs
Values for all relevant costs were included. The incremen-
tal cost of implementing the screening program included
the costs of treating true HIV positive and false HIV posi-
tive mothers while pregnant, the treatment associated
with early diagnosis in HIV positive mothers after delivery
and HIV positive children, and the avoided treatment
costs from preventing a case of HIV. The cost savings were
deducted from all other positive costs to derive a net cost
of the alternate screening strategy. It was assumed that all
women would receive pre and post test counseling. An
EIA test would be used for women who were screened by
14 weeks during antenatal care and rapid point of care test
(Orasure®) for those women screened at the onset of
labour or those infants screened within 24 hours birth. All
positives were confirmed with a western blot. For false
positives from rapid testing, treatment would be offered
because a confirmation of HIV status would not be avail-
able before treatment would have to be commenced. For
all infants born to HIV positive mothers, confirmation of
their HIV status would be through the use of a HIV
Polymerase Chain Reaction (PCR) test at time intervals in
line with the U.S. Preventive Services Taskforce Guidelines
[2]. All true positives and false positives identified at the
onset of labor or by screening the infant after birth would
begin appropriate medical therapy in accordance with
current guidelines including prophylaxis for infants born
to HIV positive mothers [7]. Medical treatment costs
would also be included for all HIV positive women up
until the time they would have been diagnosed by other
means, with similar costs included for all infants who
contract HIV despite screening and prophylaxis up until
the time they would have otherwise been diagnosed. The
lifetime costs of treating a case of HIV were determined
from the rate of disease progression of the infant. For each
case of HIV avoided, the lifetime costs of treatment andPage 2 of 10
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from the total costs of screening and treatment to derive
the net cost of the strategy.
Incremental Benefits
Incremental benefits were measured in life years gained
(LYG). These included the LYG from avoided HIV infec-
tion in infants, and the LYG from earlier detection and
treatment of HIV positive mothers and HIV positive
infants. In the repeat screening strategies (i.e. E, F, G, H, I
& J) the conservative assumption was made that if a
woman refused a first test offer, she would refuse all sub-
sequent test offers. Using the prevalence of HIV and the
sensitivity and specificity of the screening test as deter-
mined from published literature, the number of true pos-
itives and false positives were estimated. It was assumed
that not all women diagnosed with HIV would accept
antiretroviral therapy (ART) for themselves but would
comply with the recommendations for infant prophy-
laxis, not breastfeeding their infant, and treatment if their
infant is HIV+. The ART and prophylaxis protocols for
both mothers and infants corresponds to the recommen-
dations from U.S. Preventive Services Taskforce [7]. Rates
of perinatal HIV transmission determined from the litera-
ture were applied to the number of true positives identi-
fied to determine the number of cases of HIV avoided.
According to current research, some HIV positive infants
would be 'fast' progressors while others would be 'normal'
progressors [22-24]. The net LYG would be the number of
LYG from an avoided case of HIV in an infant adjusted for
their expected rate of disease progression had they con-
tracted HIV, the LYG from the earlier diagnosis of a HIV
positive mother and, the earlier diagnosis of an infant
who still contracts HIV despite screening and prophylaxis
also adjusted by their expected rate of disease progression.
Uncertainty and sensitivity analyses
For all variables, the base case, low and high values and
the source are presented in Tables 1, 2, 3, 4. The variables
for which the model results were most sensitive were iden-
tified through a series of one-way sensitivity analyses and
this information was summarized in a tornado diagram.
These variables were rigorously tested using a threshold
and two way sensitivity analysis. To further test the robust-
ness of results to uncertainty within the model, a micro-
simulation was performed (n = 10,000
microsimulations). The intention of a microsimulation is
to demonstrate variability in a population and therefore
test first order uncertainty in the model. It involves run-
ning one patient at a time through the model with the
events based on the underlying probabilities in the
model. The costs, effects and net monetary benefits are
calculated for each run through the model for each strat-
egy.
Results
With model variables set to baseline values, all strategies
generate health benefits and reduce costs when compared
Existing Practice and the Nine Alternate Models of Perinatal HIV ScreeningFigure 1
Existing Practice and the Nine Alternate Models of Perinatal HIV Screening.
Existing Practice 
A  Sporadic screening (existing practice) 
Alternatives 
B Universal screening by 14 weeks gestation 
C Universal screening at the onset of labour 
D Universal screening of infants at birth 
E Universal screening by 14 weeks gestation OR  screening at the onset of labour 
F Universal screening by 14 weeks gestation  OR  screening the infants at birth 
G Universal screening at the onset of labour  OR  screening of infants at birth 
H Universal screening by 14 weeks gestation  OR screening at the onset of labour OR screening of infants at birth 
I Universal screening by 14 weeks gestation  AND  screening at the onset of labour 
J Universal screening by 14 weeks gestation  AND  screening of the infants at birthPage 3 of 10
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is Strategy J, Universal screening by 14 weeks gestation
AND screening of the infant at birth. This will save
$737.30 and generate 0.2037 life years per pregnant
women, per annum. Generalizing to the population of the
U.S. Virgin islands of 1522 unscreened pregnant women,
the implementation of Strategy J would save $1,122,779
and generate 310 life years. As compared to existing prac-
tice, the strategy would save $2,209,564, generate 310 life
years, identify an additional 48.14 cases of HIV in moth-
ers and avoid 7.94 cases of HIV in infants. All remaining
strategies were dominated by J, that is, they were more
costly and less effective. A summary of the results includ-
ing the cost, effect, incremental cost and incremental
effect for each strategy is presented in Table 5. The cost
and effect results for each strategy are presented in Figure
2.
The finding that Strategy J was optimal is robust to uncer-
tainty in most model parameters. The best decision
changed to strategy H when the life expectancy of a HIV
positive mother with normal diagnosis (i.e. not diagnosed
via the screening strategy) was less than 15.9 years or the
rate of HIV transmission from mother to infants without
treatment was greater than 19.5%. The results of the
microsimulation suggest all strategies were dominated by
Strategy J, with Strategy J saving $1079.38 (SD $17,735)
and gain 0.2377 (SD 2.32) life years per antenatal mem-
ber per annum and save $1.6 million and gain 362 life
years when the entire unscreened antenatal population is
considered.
Table 1: Cost Variables (Labour, Counseling & Testing, Training and Health Promotion) used in model with 'baseline', 'low' and 'high' 
values, and sources
Variable Baseline (Low, High) Source
Monthly laboratory technician salary $2974 ($2230, $3717) [33]
Monthly nurses salary $4811 ($3608, $6013) [33-35]
Hourly nurses salary $27.75 ($20.81,$34.69) [33-35]
Monthly physicians salary $16,141 ($12,105, $20,176) [18,36]
Hourly physician salary $74.50 ($55.87, $93.12) [18,36]
Benefits Loading 30% (25%, 35%) [33,36]
False Positive Rate Elisa Testing 0.005 (0.001, 0.2) [37,38]
Sensitivity Elisa Testing 0.98 (0.96, 1.0) [37,38]
False Positive Rate Rapid Testing (Oraquick Advance) 0.002 (0.001, 0.2) [39]
Sensitivity Rapid Testing (Oraquick Advance – Oral Fluid) 0.993 (0.97, 1.0) [39]
Elisa cost per test $4.80 ($3.60, $6.00) [40]
Western Blot cost per test $48.50 ($36.38, $60.63) [40]
Rapid Test cost per test (Oraquick Advance) $12.00 ($9.00, $15.00) [39,40]
HIV PCR cost per test $205.00 ($153.75, $256.25) [40]
Monthly laboratory staff allocation – Elisa Test 0.17 (0, 0.34) [18]
Monthly laboratory staff allocation – Western Blot 0.17 (0, 0.34) [18]
Monthly laboratory staff allocation – HIV PCR 0.17 (0, 0.34) [18]
Monthly nurse allocation – antenatal care – Elisa test 0 (0, 0.5) [17,18]
Monthly nurse allocation – labour and delivery – rapid test 0 (0, 0.5) [17,18,39]
Monthly nurse allocation – Nursery – rapid test 0 (0, 0.5) [17,18,39]
Pre Test Counseling time – antenatal care (hours) 0.125 (0.094, 0.156) [17,18,41]
Post Test Counseling time – antenatal care (hours) 0.17 (0.128, 0.213) [17,18,41]
Pre Test Counseling time – labour or post birth (hours) 0.17 (0.128, 0.213) [17,18,41]
Post Test Counseling time – labour or post birth (hours) 0.17 (0.128, 0.213) [17,18,41]
Results Release – HIV- time 0.08 (0.00, 0.10) [17,18]
Results Release – HIV+ time 0.5 (0.25, 0.75) [17,18]
# of nurses to be trained – Elisa Test (obstetrics clinic) 32 (24, 40) [17,34]
# of nurses to be trained – Rapid Test (labour and delivery) 34 (25, 43) [17,34]
# of nurses to be trained – Rapid Test (nursery) 26 (19, 33) [17,34]
# of training sessions – Elisa Test 4 (2, 6) [18]
# of training sessions – Rapid Test 4 (2, 6) [18]
Length of training – Elisa Test (hours) 4.0 (3.0, 5.0) [18]
Length of training – Rapid Test (hours) 4.0 (3.0, 5.0) [18,39]
Training catering costs $7.50 ($5.00, $10.00) [18,42]
Investment in audiovisual equipment $5000 ($3750, $6250) [42]
Health Promotion activities set up cost $2,500 ($1875, $3125) [42]
Annual cost written media items $3,900 ($2925, $4875)) [42]
Annual cost electronic media items $25,700 ($19,275, $32,125) [42]Page 4 of 10
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Table 2: Cost Variables (HIV Treatment – Mother) used in model with 'baseline', 'low' and 'high' values, and sources
Variable Baseline (Low, High) Source
Antiretroviral medications – pre delivery per month $600 ($450, $750) [40]
# of months of medications pre delivery 6 (3, 9) [2,18]
Antiretroviral Medications – during delivery $400 ($300, $500) [40]
Antiretroviral Medications – post delivery per month $650 ($487.50, $812.50) [40]
Length Physician consults – pre delivery 0.50 (0.37, 0.63) [18]
# Physician consults – pre delivery (per month) 1 (0.5,1.5) [17,18]
Length of pre delivery period (months) 6 (3, 9) [2,18]
Length Physician consults – post delivery 0.50 (0.37, 0.63) [18]
# of Physician consults – post delivery (per month) 2.00 [18]
CD4+ cell count – # per month pre delivery 0.33 (0,25 0.5) [17,18]
CD4+ cell count – # during delivery 1 (0, 1) [17,18]
CD4+ cell count – # per month post delivery 0.33 (0.25, 0.5) [18]
Viral load – # per month pre delivery 0.33 (0.25, 0.5) [17,18]
Viral load – # during delivery 1 (0, 1) [17,18]
Viral load – # per month post delivery 0.33 (0.25, 0.5) [18]
FBC # per month pre delivery 0.33 (0.25, 0.5) [17,18]
FBC # during delivery 1 (0, 1) [17,18]
FBC # per month post delivery 0.33 (0.25, 0.5) [18]
Hepatitis A, B, C # per month 0.083 (0, 0.17) [18]
CD4+ cell count unit cost $50 ($37.50, $62.50) [40]
Viral Load unit cost $205 ($153.75, $256.25) [40]
Full Blood Count unit cost $10 ($7.50, $12.50) [40]
Hepatitis A, B, C unit cost $50 ($37.50, $62.50) [40]
Pregnancy termination unit cost $500 ($200, $700) [17,43]
Table 3: Cost Variables (HIV Treatment – Child) used in model with 'baseline', 'low' and 'high' values, and sources
Variable Baseline (Low, High) Source
Prophylactic antiretroviral medications per week $150 ($112.50, $187.50) [40]
Duration prophylactic medications (weeks) 6 (4.5,7.5) [2,18,44]
Duration prophylactic medications (weeks) for false positives 2 (0, 4) [18]
# of HIV PCR tests – prophylactic period 4 (2, 6) [18]
# of Elisas performed in prophylactic period 2 (0, 4) [18]
# of physician consults during prophylactic period 19 (14, 24) [18,44]
# of physician consultations in prophylactic period for false positives 2 (0, 4) [18]
Length of physician consult (hours) 0.25 (0.18, 0.31) [18,44]
CD4+ cell count – # per month HIV+ infant 0.33 (0.25, 0.5) [18,45]
Viral load – # per month HIV+ infant 0.33 (0.25, 0.5) [18,45]
Full blood count – # per month HIV+ infant 0.33 (0.25, 0.5) [18,45]
Confirmation HIV PCR test unit cost $205 ($153.75, $256.25) [40]
CD4+ cell count unit cost $50 ($37.50, $62.50) [40]
Viral Load unit cost $205 ($153.75, $256.25) [40]
Full Blood Count unit cost $10 ($7.50, $12.50) [40]
Cost ART for a HIV+ infant per month $650 ($487.50, $812.50) [40]
Infant formula cost per month $81 ($60.75, $101.25) [44]
# of months formula fed 12 (9, 15) [44]
Lifetime health care costs of HIV+ infant – normal progressor $408,375 [30]
Average cost per year – HIV phase $4063 ($3047, $5078) [18,30]
Average cost per year – AIDS phase $13,836 ($10,377, $17,295) [18,30]
Caregiver costs per year (HIV phase) $9912 ($7434, $12,390) [18,31]
Caregiver costs per year (AIDS phase) $27,604 ($20,703, $34,505) [18,31]
BMC Infectious Diseases 2008, 8:174 http://www.biomedcentral.com/1471-2334/8/174Discussion
The results indicate all strategies are cost saving and gen-
erate health benefits, even strategies that involve repeat
screening. This suggests that a decision not to implement
universal screening in a setting where prevalence is high
and effective therapies can be delivered is unethical.
Excess costs will be incurred and life years lost at the same
time.
The strategy with the greatest saving and the greatest LYG
is Strategy J, universal screening by 14 weeks gestation
AND screening of the infant at birth. This will inform the
mother of her HIV status if she was not screened by 14
weeks and update the mother if she was screened earlier as
some women may have contracted the virus during their
pregnancy and some may have not seroconverted at the
time of their initial screening. Strategy J was robust to
most changes within the model, including a 5% discount
rate for future costs and benefits, but not all. When 'life
expectancy of a HIV+ mother with normal diagnosis' took
a value of 15.9 years or greater, Strategy J loses its domi-
nance to Strategy H.
The conclusion also changes when alternate values for the
rate of transmission with no treatment are applied. For
lower values, Strategy H is the optimal strategy. For higher
values, Strategy J is the optimal strategy. Previous studies
have also found that their results have been sensitive to
the efficacy of treatment but the likelihood that the trans-
mission rate is as low as 19.5% is minimal [12,25]. While
transmission rates have been reported as low as 13%, the
majority of the studies report transmission rates greater
than 25% [26].
In addition to providing clear policy advice, this study is
novel due to the comprehensive range of screening
options evaluated. The authors of most studies only eval-
uate screening women once, at one point in time
Table 4: Benefit Variables used in model with 'baseline', 'low' and 'high' values, and sources
Variable Baseline (Low, High) Source
Percentage of pregnant women unscreened through existing practice 70% (50%, 90%) [17,18]
Annual population pregnant women 1522 (1142, 1903) [20]
Percentage pregnant women that accept screening – 14 wks gestation 95% (63%, 100%) [17,46-48]
Percentage pregnant women that accept screening – onset of labour 85% (67%, 100%) [17,49,50]
Percentage pregnant women that accept screening – infant at birth 90% (67%, 100%) [17,50]
Percentage pregnant women that accept ART – 14 wks gestation 75% (50%, 95%) [18,51]
Percentage pregnant women that accept ART – onset of labour 75% (50%, 100%) [18]
Percentage of pregnant women that accept ART – infant after birth 75% (50%, 100%) [18]
Prevalence of undiagnosed HIV in women of childbearing age 4.9% (3.6%, 6.1%) [18,52]
Additional percentage of screened women who hadn't seroconverted at time of first test or contracted HIV 
since first test
2% (0%, 6%) [17,25,50]
% of women who seek antenatal care prior by 14 weeks gestation 63.4% (47.6%, 79.4%) [17,20]
% of women who seek antenatal care after 14 weeks and present to hospital in sufficient time prior to 
delivery
25.2% (19.5%, 32.5%) [17,20]
Termination of pregnancy in diagnosed HIV+ mothers 1% (0%, 5%) [17,53]
TR without treatment – no breastfeeding 28% (16%, 33%) [2-4]
TR with treatment from 14 wks gestation- no breastfeeding 2% (1%, 7.3%) [4,5,54]
TR with treatment from onset of labour – no breastfeeding 10% (5%, 15%) [4,14,15]
TR with treatment within 24 hours birth – no breastfeeding 13.1% (8.9%, 17.3%) [15,16]
Life Expectancy HIV- infant 77.74 (58, 97) [20]
Time to Diagnosis of HIV+ infant without screening (months) 5.2 (3.9. 13.0) [55,56]
HIV+ infant – % FP 25% (5%, 40%) [22-24]
HIV + infant – Time in HIV phase NP (screened) (yrs) 8.5 (5.7, 13.5) [57]
HIV+ infant – Time in HIV phase NP (unscreened) (yrs) 6.2 (4.7, 8.5) [57]
HIV+ infant – Time in HIV phase FP (screened) (yrs) 0.75 (0.25, 1.25) [18,57]
HIV+ infant – Time in HIV phase FP (unscreened) (yrs) 0.5 (0.0, 1.0) [18,57]
HIV+ infant – Time in AIDS phase NP (screened) (yrs) 4.6 (1.7, 10.3) [18,57]
HIV+ infant – Time in AIDS phase NP (unscreened) (yrs) 3.9 (1.5, 9.7) [57]
HIV+ infant – Time in AIDS phase FP (screened) (yrs) 0.75 (0.25, 1.25) [22-24]
HIV+ infant – Time in AIDS phase FP (unscreened) (yrs) 0.5 (0.0, 1.0) [18,22-24]
Life expectancy HIV+ mother from diagnosis (normal diagnosis path) (years) 12.0 (9.8, 18.2) [58]
Life expectancy HIV+ mother from diagnosis (early diagnosis due to screening) (years) 12.70 (9.9, 15.0) [58]
Time to diagnosis of HIV+ mother without screening (months) 20.4 (15.0, 25.5) [58]
TR = Transmission Rate
FP = Fast Progressor
NP = Normal ProgressorPage 6 of 10
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Table 5: Average and Incremental Cost and Effect Outcomes per Pregnant Woman per Annum
Strategy Cost ($) Effect (LYG) Incremental Cost ($) Incremental Effect (LYG) ICER
J Universal screening by 14 weeks gestation 
and screening of the infant at birth
-737.70 0.2037
H Universal screening by 14 weeks gestation 
or screening at the onset of labour or 
screening of the infant at birth
-730.55 0.2013 7.15 -0.0023 Dominated
F Universal screening by 14 weeks gestation 
or screening of the infant at birth
-718.82 0.2001 18.88 -0.0036 Dominated
I Universal screening by 14 weeks gestation 
and screening at the onset of labour
-646.90 0.1627 90.81 -0.0409 Dominated
E Universal screening by 14 weeks gestation 
or screening at the onset of labour
-639.95 0.1636 97.76 -0.0400 Dominated
B Universal screening by 14 weeks gestation -600.54 0.1485 137.16 -0.0552 Dominated
G Universal screening at the onset of labour 
or screening the infant at birth
-298.17 0.1443 439.54 -0.0594 Dominated
C Universal screening at the onset of labour -89.46 0.0389 648.24 -0.1648 Dominated
D Universal screening of the infant at birth -75.02 0.1409 662.69 -0.0628 Dominated
A Sporadic screening 714.05 0.0000 1451.75 -0.2037 Dominated
Cost-Effectiveness Plane – Alternate Strategies for Perinatal HIV Screening – US Virgin IslandsFigure 2
Cost-Effectiveness Plane – Alternate Strategies for Perinatal HIV Screening – US Virgin Islands.
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pared screening women at more than one point in time
[22-24] and none have compared the 'AND' strategies (i.e.
strategies I and J) included in this evaluation. The conclu-
sion that repeat screening is cost-effective is therefore
novel. The model structure also allows the impact of dif-
ferent rates of disease progression in the infant [22-24],
the additional benefits to the mother and infant from
early diagnosis, the cost of caring for a child with HIV and
AIDS [30,31], the medical costs of a child with HIV and
AIDS and the impact of rapid testing [18].
There are several limitations to this research that warrant
further investigation. There is little research into the
acceptance of a blood specimen as opposed to a saliva
specimen for rapid testing and this may affect compliance
to testing. Little is known about whether the acceptance of
screening may differ between different races, ethnicities
and socioeconomic groups. There is also little evidence of
the acceptance of HIV treatment recommendations by a
mother including the acceptance of treatment for her
HIV+ infant and avoiding breastfeeding her HIV+ or HIV-
infant. There is the potential that further testing of the
mother and/or infant may be required to assess compli-
ance which is not addressed in this study. In addition, the
literature indicates that the earlier a woman is diagnosed
and ART commenced, the greater the potential to avert
virus transmission to the infant. In this study, if a woman
does not attend prenatal care by 14 weeks gestation, the
next time she would be offered screening is at the onset of
labor. There would be a greater potential to avert virus
transmission for those who do not attend prenatal care by
14 weeks if they were offered screening earlier than at the
onset of labor. These potential additional benefits are not
addressed in this study. There is limited data for any pop-
ulation on the incidence of women who seroconvert after
the time of their initial test or the incidence of women
who contract HIV after their initial screen. This informa-
tion would be of importance in reinforcing the benefits of
offering screening at during more than just the prenatal
visit before 14 weeks gestation. Our understanding of the
life expectancy of a HIV positive infant, the lifetime health
care costs of a HIV positive infant and the treatment
regimes for children are constantly changing. Such
changes often mean that the previously published litera-
ture does not truly reflect the effectiveness of current prac-
tice. While we believe that our high and low values for
these variables are reasonable and our conclusions are
robust to these changes, the continuing improvements in
clinical practice should be monitored to ensure that the
values for these variables are as reflective as possible of the
true cost and effectiveness of current treatment. While the
results of the microsimulation demonstrate possible vari-
ation in population characteristics, the value of a variable
for each simulation is chosen randomly on all levels. Had
probability distributions been fitted to model parameters
then second order (parameter) uncertainty could have
been characterized and cost-effectiveness acceptability
curves fitted. This framework also allows the value of
reducing uncertainty in model parameters to be esti-
mated, thus providing a valuation of further data collec-
tion in the future.
This study highlights that the decision of the U.S. Virgin
Islands to adopt standard U.S. policy for perinatal HIV
screening is inefficient. Women need to be offered screen-
ing more than once and at different points in time. A
change to this policy, we suggest, would represent an
excellent public health investment, saving nearly 310 life
years with an ultimate costs saving of over $1.1 million
when the entire antenatal population is considered. The
study has not only addressed the unique characteristics of
the U.S. Virgin Islands but has addressed the cost-effec-
tiveness of antenatal HIV screening for a lower high
income country, a country with relatively high HIV preva-
lence yet relatively substantial resources available to be
dedicated to health care. To date, other studies have
addressed either high income countries [8,9,25,29,32], or
low or lower middle income countries [10,11] but their
recommendations are generally not applicable to upper
middle income or lower high income countries. These
countries may not have the resources to implement strat-
egies recommended for upper high income countries as
the range of countries classified as high income is very
broad, yet can do more than those recommendations for
low income or lower middle income country. Puerto Rico
is one country that these results might be generalized to.
It is a U.S. Territory that adopts much of its healthcare pol-
icy from the mainland U.S. Like the U.S. Virgin Islands, it
is a lower upper middle income country with resources
available for healthcare. The two countries have similar
rates of antenatal care, HIV prevalence greater than that of
the mainland U.S. and cases of vertically transmitted HIV
are still being diagnosed. Furthermore, both countries are
in similar geographical regions with similar population
characteristics with Puerto Rico having a higher portion of
its population of Hispanic ethnicity. There are several
other countries that these results may be generalisable to.
While none are as similar in characteristics as Puerto Rico,
a country with a similar gross domestic product, mainly
upper middle and lower high income countries might
benefit from this research owing to the fact that these
countries may not have the resources available to imple-
ment screening strategies recommended for upper high
income countries, yet can do more than the recom-
mended strategies for low income countries. Countries
that may fall into this category include other U.S. Territo-
ries (Guam and American Samoa), other Caribbean coun-
tries (The Bahamas, Aruba, Barbados, St Lucia, St Kitts and
Nevis) and even countries within the Americas andPage 8 of 10
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order to generalize, consideration would need to be given
to HIV prevalence in women of child bearing age, the rates
of prenatal care in the country, acceptance of screening,
population and cultural characteristics and the pricing
and availability of treatment. Furthermore, the incremen-
tal analysis of this study only accounts for the new inputs
that are required and does not consider the total costs by
including the costs of the existing program. To ensure gen-
eralisability between settings, existing program costs,
including infrastructure, of the settings would need to be
accounted for.
Conclusion
This study demonstrates the inefficiency of adopting
standard perinatal HIV screening policies without
addressing a regions population characteristics, HIV prev-
alence, and the resources available for healthcare. The
conclusions provide an opportunity to develop clear,
unambiguous and practical policy that will drive costs
downward and deliver increased health benefits. This rep-
resents an improvement in economic efficiency and a pos-
itive step toward treating a serious and prevalent disease.
Additionally, this study highlights the benefits of offering
screening at different opportunities and of repeat screen-
ing. The findings of this study are not only useful to the
U.S. Virgin Islands, but raise the question of the generalis-
ability of these results to countries that share similar eco-
nomic, epidemiological and social characteristics.
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